Conduit Pharmaceuticals I... (CDT)
0.91
0.04 (4.83%)
At close: Apr 15, 2025, 3:59 PM
0.87
-3.49%
After-hours: Apr 15, 2025, 07:59 PM EDT
Company Description
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility.
It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility.
The company was founded in 2019 and is based in San Diego, California.
Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Mar 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. David Joszef Tapolczay |
Contact Details
Address: 4995 Murphy Canyon Road San Diego, California United States | |
| Website | https://www.conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000913142 |
| CUSIP Number | 20678X106 |
| ISIN Number | US20678X1063 |
| Employer ID | 36-3601505 |
| SIC Code | 3357 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Joszef Tapolczay | Chief Executive Officer & Director |
| James Bligh | Interim Chief Financial Officer & Director |
| Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 08, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | 8-K | Current Report |
| Apr 02, 2025 | 8-K/A | [Amend] Current Report |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |